Notes
International Society for Pharmacoeconomics and Outcomes Research
2019 US dollars
Reference
Williamson T, et al. Economic Analysis of Inpatient Adverse Event-Related Expenditures in Metastatic Solid Tumor Patients Exposed to Larotrectinib or Entrectinib. 25th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research : (plus poster) abstr. N/A, 18 May 2020. Available from: URL: https://www.ispor.org/heor-resources/presentations-database/presentation/intl2020-3182/98929
Rights and permissions
About this article
Cite this article
SAE-related costs lower with larotrectinib than with entrectinib. PharmacoEcon Outcomes News 855, 27 (2020). https://doi.org/10.1007/s40274-020-6892-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-020-6892-4